2022
Post‐treatment effects of topiramate on alcohol‐related outcomes: A combined analysis of two placebo‐controlled trials
Kranzler HR, Feinn R, Pond T, Hartwell E, Gelernter J, Crist RC, Witkiewitz K. Post‐treatment effects of topiramate on alcohol‐related outcomes: A combined analysis of two placebo‐controlled trials. Addiction Biology 2022, 27: e13130. PMID: 35229945, PMCID: PMC9257958, DOI: 10.1111/adb.13130.Peer-Reviewed Original ResearchMeSH KeywordsAlcohol DrinkingAlcoholismDouble-Blind MethodFemaleFructoseHumansMaleMiddle AgedReceptors, Kainic AcidTopiramateConceptsAlcohol use disorderPost-treatment periodAlcohol-related outcomesAlcohol-related problemsTopiramate's effectsSingle nucleotide polymorphismsPlacebo-controlled trialPrimary treatment outcomeOptimal treatment durationSelf-reported alcohol consumptionTrial of topiramatePost-treatment effectsTopiramate groupPlacebo groupSecond RCTMedication effectsTreatment outcomesProblematic alcohol useTopiramateTreatment durationUse disordersAlcohol consumptionΓ-glutamyltransferaseRobust effectGenotype groups
2017
GRIK1 and GABRA2 Variants Have Distinct Effects on the Dose‐Related Subjective Response to Intravenous Alcohol in Healthy Social Drinkers
Yang B, Arias AJ, Feinn R, Krystal JH, Gelernter J, Petrakis IL. GRIK1 and GABRA2 Variants Have Distinct Effects on the Dose‐Related Subjective Response to Intravenous Alcohol in Healthy Social Drinkers. Alcohol Clinical And Experimental Research 2017, 41: 2025-2032. PMID: 29131352, PMCID: PMC5764175, DOI: 10.1111/acer.13516.Peer-Reviewed Original Research
2014
Topiramate Treatment for Heavy Drinkers: Moderation by a GRIK1 Polymorphism
Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ, Gelernter J, Pond T, Oncken C, Kampman KM. Topiramate Treatment for Heavy Drinkers: Moderation by a GRIK1 Polymorphism. American Journal Of Psychiatry 2014, 171: 445-452. PMID: 24525690, PMCID: PMC3997125, DOI: 10.1176/appi.ajp.2013.13081014.Peer-Reviewed Original ResearchConceptsHeavy drinking daysHeavy drinkersTopiramate treatmentDaily doseHeavy drinkingTopiramate's effectsDrinking daysAbstinent daysUse of topiramateMaximal daily doseWeeks of treatmentC allele homozygotesPersonalized treatment optionsEnzyme γ-glutamyl transpeptidasePlacebo groupΓ-glutamyl transpeptidaseTreatment optionsTreatment completionPharmacogenetic findingsTreatment goalsAlcohol-related problemsKainate receptorsTreatment groupsBrief counselingAlcohol dependence
2007
Population-specific effects of the Asn40Asp polymorphism at the μ-opioid receptor gene (OPRM1) on HPA-axis activation
Hernandez-Avila CA, Covault J, Wand G, Zhang H, Gelernter J, Kranzler HR. Population-specific effects of the Asn40Asp polymorphism at the μ-opioid receptor gene (OPRM1) on HPA-axis activation. Pharmacogenetics And Genomics 2007, 17: 1031-1038. PMID: 18004207, DOI: 10.1097/fpc.0b013e3282f0b99c.Peer-Reviewed Original ResearchMeSH KeywordsAdrenocorticotropic HormoneAdultAllelesAmino Acid SubstitutionAsian PeopleDouble-Blind MethodFemaleGenetics, PopulationGenotypeHumansHydrocortisoneHypothalamo-Hypophyseal SystemMaleNaloxonePharmacogeneticsPituitary-Adrenal SystemPolymorphism, Single NucleotideReceptors, Opioid, muWhite PeopleConceptsHPA axis activationCortisol responseAsn40 homozygotesAsn40Asp polymorphismAsp40 alleleSingle nucleotide polymorphism A118GHPA axis responsePlacebo-controlled administrationΜ-opioid receptor geneGreater cortisol responseIntravenous naloxoneOpioid blockadeAxis activationAdrenocorticotropic hormoneA118GHealthy individualsOPRM1 SNPsNaloxoneCortisol concentrationsHormonal responsesEuropean AmericansObserved associationsHealthy participantsWhole bloodReceptor geneOpioid Receptor Gene (OPRM1, OPRK1, and OPRD1) Variants and Response to Naltrexone Treatment for Alcohol Dependence: Results From the VA Cooperative Study
Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH, Group T. Opioid Receptor Gene (OPRM1, OPRK1, and OPRD1) Variants and Response to Naltrexone Treatment for Alcohol Dependence: Results From the VA Cooperative Study. Alcohol Clinical And Experimental Research 2007, 31: 555-563. PMID: 17374034, DOI: 10.1111/j.1530-0277.2007.00339.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcoholismConfidence IntervalsDNADouble-Blind MethodExonsFemaleGenetic VariationGenotypeHumansLinear ModelsLogistic ModelsMaleMiddle AgedNaltrexoneNarcotic AntagonistsOdds RatioProportional Hazards ModelsPsychiatric Status Rating ScalesReceptors, Opioid, deltaReceptors, Opioid, kappaReceptors, Opioid, muSmokingTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsConceptsAlcohol dependenceOpioid receptorsTreatment responseVA Cooperative StudyRate of relapsePredictors of responseAlcohol-dependent male subjectsMu-opioid receptorsKappa-opioid receptorsCourse of treatmentShort-term treatmentReceptor gene variantsOpioid receptor geneAsn40Asp polymorphismAvailable medicationsNaltrexone treatmentSpecific pharmacotherapyPretreatment numberDrug naltrexoneNaltrexoneMale subjectsCooperative StudyRelapseHeavy drinkingIndividual single nucleotide polymorphisms
2006
C957T polymorphism of the dopamine D2 receptor gene modulates the effect of nicotine on working memory performance and cortical processing efficiency
Jacobsen LK, Pugh KR, Mencl WE, Gelernter J. C957T polymorphism of the dopamine D2 receptor gene modulates the effect of nicotine on working memory performance and cortical processing efficiency. Psychopharmacology 2006, 188: 530-540. PMID: 16896957, DOI: 10.1007/s00213-006-0469-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultBrainDouble-Blind MethodFemaleGenotypeHumansMaleMemoryNicotineNicotinic AgonistsPolymorphism, GeneticReceptors, Dopamine D2SmokingConceptsMemory performanceEffects of nicotineBrain regionsBrain functionFunctional magnetic resonanceCortical processing efficiencyRange of behavioralC957T polymorphismProcessing efficiencyPhonological rehearsalMemory taskMemory loadBrain responsesPerformance accuracyC957TMemoryBehavioral effectsNicotine administrationDopamine D2 receptor geneConclusionsThese findingsTobacco dependenceIndividual variationIndividual responsesTaskPlacebo patch
2004
Altered NMDA Glutamate Receptor Antagonist Response in Individuals With a Family Vulnerability to Alcoholism
Petrakis IL, Limoncelli D, Gueorguieva R, Jatlow P, Boutros NN, Trevisan L, Gelernter J, Krystal JH. Altered NMDA Glutamate Receptor Antagonist Response in Individuals With a Family Vulnerability to Alcoholism. American Journal Of Psychiatry 2004, 161: 1776-1782. PMID: 15465973, DOI: 10.1176/ajp.161.10.1776.Peer-Reviewed Original ResearchAdultAffectAlcohol DrinkingAlcoholic IntoxicationAlcoholismBrief Psychiatric Rating ScaleDissociative DisordersDouble-Blind MethodEthanolFamilyFemaleGenetic Predisposition to DiseaseHumansInfusions, IntravenousKetamineMalePedigreePlacebosPsychoses, AlcoholicReceptors, N-Methyl-D-AspartateRisk Factors
1994
Allelic Variation in the D4 Dopamine Receptor (DRD4) Gene Does Not Predict Response to Clozapine
Rao PA, Pickar D, Gejman PV, Ram A, Gershon ES, Gelernter J. Allelic Variation in the D4 Dopamine Receptor (DRD4) Gene Does Not Predict Response to Clozapine. JAMA Psychiatry 1994, 51: 912-917. PMID: 7944879, DOI: 10.1001/archpsyc.1994.03950110072009.Peer-Reviewed Original ResearchConceptsClinical responseTherapeutic effectAtypical antipsychotic drug clozapineClozapine's therapeutic effectsTreatment-refractory schizophreniaPathophysiology of schizophreniaAntipsychotic drug clozapineD4 dopamine receptorsDRD4 allelesPutative third cytoplasmic loopSchizoaffective patientsTherapeutic responseTherapy variesDopamine receptorsSchizoaffective subjectsTreatment responseThird cytoplasmic loopDrug clozapineClozapineDopamine receptor geneSchizoaffective disorderD4 receptorsPolymerase chain reaction amplificationReceptor allelesChain reaction amplification